{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:42:36Z","timestamp":1788298956484,"version":"build-2803163510"},"reference-count":118,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2024.2757","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T11:26:00Z","timestamp":1719573960000},"source":"Crossref","is-referenced-by-count":6,"title":["Emerging applications of hypomethylating agents in the treatment of glioblastoma (Review)"],"prefix":"10.3892","volume":"21","author":[{"given":"Thenzing","family":"Silva\u2011Hurtado","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Inocencio","sequence":"additional","affiliation":[{"name":"Leo M. Davidoff Department of Neurosurgery, Montefiore Medical Center, Einstein College of Medicine, Bronx, NY 10461, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymund","family":"Yong","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"key20240801123844_b1-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.1065173","article-title":"Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor","volume":"295","author":"Di Croce","year":"2002","journal-title":"Science"},{"key":"key20240801123844_b2-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature10866","article-title":"IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype","volume":"483","author":"Turcan","year":"2012","journal-title":"Nature"},{"key":"key20240801123844_b3-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"key20240801123844_b4-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"key20240801123844_b5-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020","volume":"25 (12 Suppl 2)","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol"},{"issue":"vdaa082","key":"key20240801123844_b6-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaa082","article-title":"Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: A systematic review and meta-analysis","volume":"2","author":"Alnahhas","year":"2020","journal-title":"Neurooncol Adv"},{"issue":"5377","key":"key20240801123844_b7-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215377","article-title":"New directions in the therapy of glioblastoma","volume":"14","author":"Szklener","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20240801123844_b8-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1161\/CIRCULATIONAHA.110.956839","article-title":"Epigenetic modifications: Basic mechanisms and role in cardiovascular disease","volume":"123","author":"Handy","year":"2011","journal-title":"Circulation"},{"issue":"64","key":"key20240801123844_b9-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-020-00857-x","article-title":"DNA methylation changes during preimplantation development reveal inter-species differences and reprogramming events at imprinted genes","volume":"12","author":"Ivanova","year":"2020","journal-title":"Clin Epigenetics"},{"issue":"10138","key":"key20240801123844_b10-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28356-3","article-title":"Dosage compensation and DNA methylation landscape of the X chromosome in mouse liver","volume":"8","author":"Duncan","year":"2018","journal-title":"Sci Rep"},{"issue":"675780","key":"key20240801123844_b11-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.675780","article-title":"Epigenetic regulation of genomic stability by vitamin C","volume":"12","author":"Brabson","year":"2021","journal-title":"Front Genet"},{"key":"key20240801123844_b12-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s13237-021-00367-y","article-title":"DNA methylation and regulation of gene expression: Guardian of our health","volume":"64","author":"Dhar","year":"2021","journal-title":"Nucleus (Calcutta)"},{"key":"key20240801123844_b13-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0092-8674(81)90248-8","article-title":"DNA methylation controls the inducibility of the mouse metallothionein-I gene lymphoid cells","volume":"25","author":"Compere","year":"1981","journal-title":"Cell"},{"key":"key20240801123844_b14-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/npp.2012.112","article-title":"DNA methylation and its basic function","volume":"38","author":"Moore","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"key20240801123844_b15-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"8905","DOI":"10.1073\/pnas.0501034102","article-title":"Recruitment of DNA methyltransferase I to DNA repair sites","volume":"102","author":"Mortusewicz","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20240801123844_b16-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/nature02633","article-title":"Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting","volume":"429","author":"Kaneda","year":"2004","journal-title":"Nature"},{"key":"key20240801123844_b17-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1006\/geno.2000.6168","article-title":"Isolation and initial characterization of a novel zinc finger gene, DNMT3L, on 21q22.3, related to the cytosine-5-methyltransferase 3 gene family","volume":"65","author":"Aapola","year":"2000","journal-title":"Genomics"},{"key":"key20240801123844_b18-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/1947601910393957","article-title":"DNA methylation: Superior or subordinate in the epigenetic hierarchy?","volume":"2","author":"Jin","year":"2011","journal-title":"Genes Cancer"},{"key":"key20240801123844_b19-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1126\/science.1697983","article-title":"5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes","volume":"249","author":"Rideout","year":"1990","journal-title":"Science"},{"key":"key20240801123844_b20-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.cell.2009.04.020","article-title":"A unifying model for the selective regulation of inducible transcription by CpG islands and nucleosome remodeling","volume":"138","author":"Ramirez-Carrozzi","year":"2009","journal-title":"Cell"},{"key":"key20240801123844_b21-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nature06008","article-title":"Genome-wide maps of chromatin state in pluripotent and lineage-committed cells","volume":"448","author":"Mikkelsen","year":"2007","journal-title":"Nature"},{"issue":"e14524","key":"key20240801123844_b22-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014524","article-title":"DNA methylation of the first exon is tightly linked to transcriptional silencing","volume":"6","author":"Brenet","year":"2011","journal-title":"PLoS One"},{"key":"key20240801123844_b23-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1126\/science.1136352","article-title":"Gene body-specific methylation on the active X chromosome","volume":"315","author":"Hellman","year":"2007","journal-title":"Science"},{"key":"key20240801123844_b24-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00412-009-0221-9","article-title":"DNA methylation and methyl-CpG binding proteins: Developmental requirements and function","volume":"118","author":"Bogdanovi\u0107","year":"2009","journal-title":"Chromosoma"},{"issue":"18","key":"key20240801123844_b25-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-018-1390-8","article-title":"Genome-wide analyses reveal a role of polycomb in promoting hypomethylation of DNA methylation valleys","volume":"19","author":"Li","year":"2018","journal-title":"Genome Biol"},{"key":"key20240801123844_b26-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.molcel.2008.05.007","article-title":"Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors","volume":"30","author":"Mohn","year":"2008","journal-title":"Mol Cell"},{"key":"key20240801123844_b27-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"10013","DOI":"10.1007\/s11033-022-07569-w","article-title":"Epigenetic insights in the diagnosis, prognosis, and treatment selection in CRC, an updated review","volume":"49","author":"Ghadiri Moghaddam","year":"2022","journal-title":"Mol Biol Rep"},{"issue":"18","key":"key20240801123844_b28-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.1186\/s13072-017-0125-5","article-title":"Links between DNA methylation and nucleosome occupancy in the human genome","volume":"10","author":"Collings","year":"2017","journal-title":"Epigenetics Chromatin"},{"key":"key20240801123844_b29-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ccell.2017.11.018","article-title":"Genomic and epigenomic profiling of high-risk intestinal metaplasia reveals molecular determinants of progression to gastric cancer","volume":"33","author":"Huang","year":"2018","journal-title":"Cancer Cell"},{"issue":"154","key":"key20240801123844_b30-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-022-01382-9","article-title":"Gene body methylation in cancer: Molecular mechanisms and clinical applications","volume":"14","author":"Wang","year":"2022","journal-title":"Clin Epigenetics"},{"key":"key20240801123844_b31-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2019.05.013","article-title":"Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use","volume":"140","author":"Santini","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20240801123844_b32-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/s1046-2023(02)00072-5","article-title":"DNA methylation and epigenetic inheritance","volume":"27","author":"Holliday","year":"2002","journal-title":"Methods"},{"key":"key20240801123844_b33-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1002\/cncr.23463","article-title":"Evolution of decitabine development: Accomplishments, ongoing investigations, and future strategies","volume":"112","author":"Jabbour","year":"2008","journal-title":"Cancer"},{"key":"key20240801123844_b34-MCO-21-3-02757","first-page":"339","article-title":"Effect of 5-aza-2'-deoxycytidine against leukemic and hemopoietic tissues in AKR mice","volume":"15","author":"Sorm","year":"1968","journal-title":"Neoplasma"},{"key":"key20240801123844_b35-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1177\/10781552211037993","article-title":"Novel agents for myelodysplastic syndromes","volume":"27","author":"Xu","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"650473","key":"key20240801123844_b36-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.650473","article-title":"Mechanisms of action of hypomethylating agents: Endogenous retroelements at the epicenter","volume":"11","author":"Kordella","year":"2021","journal-title":"Front Oncol"},{"key":"key20240801123844_b37-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nrclinonc.2010.87","article-title":"Therapy with azanucleosides for myelodysplastic syndromes","volume":"7","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"e9001","key":"key20240801123844_b38-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009001","article-title":"A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines","volume":"5","author":"Hollenbach","year":"2010","journal-title":"PLoS One"},{"key":"key20240801123844_b39-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/03602532.2018.1437446","article-title":"Effects of 5-Aza-2'-deoxycytidine (decitabine) on gene expression","volume":"50","author":"Seelan","year":"2018","journal-title":"Drug Metab Rev"},{"key":"key20240801123844_b40-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00280-007-0531-7","article-title":"Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)","volume":"61","author":"Cashen","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20240801123844_b41-MCO-21-3-02757","first-page":"592","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs","volume":"43","author":"Chabot","year":"1983","journal-title":"Cancer Res"},{"key":"key20240801123844_b42-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1158\/1078-0432.CCR-21-4498","article-title":"FDA approval summary: Decitabine and cedazuridine tablets for myelodysplastic syndromes","volume":"28","author":"Kim","year":"2022","journal-title":"Clin Cancer Res"},{"key":"key20240801123844_b43-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"key20240801123844_b44-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"key20240801123844_b45-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-3-642-01222-8_11","article-title":"5-Azacytidine\/azacitidine","volume":"184","author":"M\u00fcller","year":"2010","journal-title":"Recent Results Cancer Res"},{"key":"key20240801123844_b46-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1517\/14656566.2013.794222","article-title":"5-Azacytidine for the treatment of myelodysplastic syndromes","volume":"14","author":"Krawczyk","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"key20240801123844_b47-MCO-21-3-02757","first-page":"737","article-title":"Azacitidine: 10 Years later","volume":"71","author":"Glover","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"key20240801123844_b48-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1634\/theoncologist.10-3-176","article-title":"FDA drug approval summary: Azacitidine (5-azacytidine, Vidaza) for injectable suspension","volume":"10","author":"Kaminskas","year":"2005","journal-title":"Oncologist"},{"key":"key20240801123844_b49-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/0091270004271947","article-title":"Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes","volume":"45","author":"Marcucci","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"key20240801123844_b50-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(19)30029-8","article-title":"Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1\/2 trial","volume":"6","author":"Garcia-Manero","year":"2019","journal-title":"Lancet Haematol"},{"key":"key20240801123844_b51-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1158\/1535-7163.MCT-09-1048","article-title":"S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth","volume":"9","author":"Chuang","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"key20240801123844_b52-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1470-2045(15)00038-8","article-title":"Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: A multicentre, randomised, dose-escalation phase 1 study","volume":"16","author":"Issa","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3217","key":"key20240801123844_b53-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0024-5","article-title":"Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer","volume":"8","author":"Ramakrishnan","year":"2017","journal-title":"Cell Death Dis"},{"key":"key20240801123844_b54-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1080\/07853890.2022.2099578","article-title":"DNA methyltransferase-1 in acute myeloid leukaemia: Beyond the maintenance of DNA methylation","volume":"54","author":"Li","year":"2022","journal-title":"Ann Med"},{"key":"key20240801123844_b55-MCO-21-3-02757","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/s43018-021-00249-x","article-title":"Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia","volume":"2","author":"Pappalardi","year":"2021","journal-title":"Nat Cancer"},{"key":"key20240801123844_b56-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/10428199909169608","article-title":"P15INK4b gene methylation and myelodysplastic syndromes","volume":"35","author":"Quesnel","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"key20240801123844_b57-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","article-title":"TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: Biology, current therapy, and future directions","volume":"12","author":"Daver","year":"2022","journal-title":"Cancer Discov"},{"key":"key20240801123844_b58-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"E138","DOI":"10.1002\/ijc.26429","article-title":"Quantitative analyses of DAPK1 methylation in AML and MDS","volume":"131","author":"Claus","year":"2012","journal-title":"Int J Cancer"},{"key":"key20240801123844_b59-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/leu.2008.397","article-title":"The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells","volume":"23","author":"Flotho","year":"2009","journal-title":"Leukemia"},{"key":"key20240801123844_b60-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1002\/cbin.11868","article-title":"DNA methylation influences the CTCF-modulated transcription of RASSF1A in lung cancer cells","volume":"46","author":"Xie","year":"2022","journal-title":"Cell Biol Int"},{"issue":"115","key":"key20240801123844_b61-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-016-0282-6","article-title":"Blood-based DNA methylation as biomarker for breast cancer: A systematic review","volume":"8","author":"Tang","year":"2016","journal-title":"Clin Epigenetics"},{"key":"key20240801123844_b62-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00432-010-0772-4","article-title":"Identification of aberrant promoter hypomethylation of HOXA10 in ovarian cancer","volume":"136","author":"Cheng","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1245","key":"key20240801123844_b63-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061245","article-title":"The tumor suppressor MTUS1\/ATIP1 modulates tumor promotion in glioma: Association with epigenetics and DNA repair","volume":"13","author":"Ranjan","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"447","key":"key20240801123844_b64-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-447","article-title":"ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma","volume":"9","author":"G\u00f6tze","year":"2009","journal-title":"BMC Cancer"},{"key":"key20240801123844_b65-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1158\/0008-5472.CAN-04-4283","article-title":"EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma","volume":"65","author":"Alaminos","year":"2005","journal-title":"Cancer Res"},{"key":"key20240801123844_b66-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.31557\/APJCP.2023.24.6.1841","article-title":"The effect of 5-aza,2'-deoxyCytidine (5 AZA CdR or decitabine) on extrinsic, intrinsic, and JAK\/STAT pathways in neuroblastoma and glioblastoma cells lines","volume":"24","author":"Sanaei","year":"2023","journal-title":"Asian Pac J Cancer Prev"},{"key":"key20240801123844_b67-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ccr.2014.07.028","article-title":"Gene body methylation can alter gene expression and is a therapeutic target in cancer","volume":"26","author":"Yang","year":"2014","journal-title":"Cancer Cell"},{"key":"key20240801123844_b68-MCO-21-3-02757","first-page":"5815","article-title":"Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9\/3 regulated and Fas\/caspase-8 independent","volume":"60","author":"Ochs","year":"2000","journal-title":"Cancer Res"},{"key":"key20240801123844_b69-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/cr.2008.270","article-title":"Promoter hypomethylation regulates CD133 expression in human gliomas","volume":"18","author":"Tabu","year":"2008","journal-title":"Cell Res"},{"key":"key20240801123844_b70-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"8094","DOI":"10.1158\/0008-5472.CAN-07-6208","article-title":"Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors","volume":"68","author":"Yi","year":"2008","journal-title":"Cancer Res"},{"key":"key20240801123844_b71-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/neuonc\/noaa074","article-title":"5-Azacitidine in patients with IDH1\/2-mutant recurrent glioma","volume":"22","author":"Federici","year":"2020","journal-title":"Neuro Oncol"},{"issue":"a026948","key":"key20240801123844_b72-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026948","article-title":"DNA Hypomethylating drugs in cancer therapy","volume":"7","author":"Sato","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"key20240801123844_b73-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-11-3909","article-title":"Epigenetic resensitization to platinum in ovarian cancer","volume":"72","author":"Matei","year":"2012","journal-title":"Cancer Res"},{"key":"key20240801123844_b74-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/sj.bjc.6605817","article-title":"Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy","volume":"103","author":"Glaysher","year":"2010","journal-title":"Br J Cancer"},{"issue":"RP88221","key":"key20240801123844_b75-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.88221","article-title":"Intrinsic protein disorder is insufficient to drive subnuclear clustering in embryonic transcription factors","volume":"12","author":"Hannon","year":"2024","journal-title":"Elife"},{"key":"key20240801123844_b76-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1158\/1535-7163.MCT-13-0924","article-title":"The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide","volume":"13","author":"Moen","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"key20240801123844_b77-MCO-21-3-02757","first-page":"6039","article-title":"Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter","volume":"60","author":"Plumb","year":"2000","journal-title":"Cancer Res"},{"key":"key20240801123844_b78-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/annonc\/mds591","article-title":"Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: A phase I\/II study and pharmacokinetic analysis","volume":"24","author":"Tawbi","year":"2013","journal-title":"Ann Oncol"},{"key":"key20240801123844_b79-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11060-013-1133-3","article-title":"Promoter methylation of AREG, HOXA11, hMLH1, NDRG2, NPTX2 and Tes genes in glioblastoma","volume":"113","author":"Skiriut\u0117","year":"2013","journal-title":"J Neurooncol"},{"issue":"e76401","key":"key20240801123844_b80-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076401","article-title":"Integrated analysis of mismatch repair system in malignant astrocytomas","volume":"8","author":"Rodr\u00edguez-Hern\u00e1ndez","year":"2013","journal-title":"PLoS One"},{"key":"key20240801123844_b81-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1158\/1078-0432.CCR-04-1625","article-title":"Promoter hypermethylation of mismatch repair gene hMLH1 predicts the clinical response of malignant astrocytomas to nitrosourea","volume":"11","author":"Fukushima","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20240801123844_b82-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s11060-020-03461-4","article-title":"Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1","volume":"147","author":"Gallitto","year":"2020","journal-title":"J Neurooncol"},{"key":"key20240801123844_b83-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1172\/JCI84940","article-title":"Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer","volume":"126","author":"Mehnert","year":"2016","journal-title":"J Clin Invest"},{"issue":"PO.17.00146","key":"key20240801123844_b84-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00146","article-title":"Identifying a clinically applicable mutational burden threshold as a potential biomarker of response to immune checkpoint therapy in solid tumors","volume":"2017","author":"Panda","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"key20240801123844_b85-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"1402","key":"key20240801123844_b86-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01402","article-title":"Molecular heterogeneity and immunosuppressive microenvironment in glioblastoma","volume":"11","author":"DeCordova","year":"2020","journal-title":"Front Immunol"},{"key":"key20240801123844_b87-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/d41586-018-07728-9","article-title":"Immune cells track hard-to-target brain tumours","volume":"565","author":"Zaidi","year":"2019","journal-title":"Nature"},{"issue":"4795","key":"key20240801123844_b88-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32311-2","article-title":"Circular EZH2-encoded EZH2-92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands","volume":"13","author":"Zhong","year":"2022","journal-title":"Nat Commun"},{"issue":"365","key":"key20240801123844_b89-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05878-x","article-title":"Epigenetically modified AP-2\u03b1 by DNA methyltransferase facilitates glioma immune evasion by upregulating PD-L1 expression","volume":"14","author":"Long","year":"2023","journal-title":"Cell Death Dis"},{"issue":"2174","key":"key20240801123844_b90-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10092174","article-title":"Epigenetic suppression of the IL-7 pathway in progressive glioblastoma","volume":"10","author":"Tompa","year":"2022","journal-title":"Biomedicines"},{"issue":"29","key":"key20240801123844_b91-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00029","article-title":"Augmenting antitumor immune responses with epigenetic modifying agents","volume":"6","author":"H\u00e9ninger","year":"2015","journal-title":"Front Immunol"},{"key":"key20240801123844_b92-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/JCI123791","article-title":"Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers","volume":"129","author":"Malekzadeh","year":"2019","journal-title":"J Clin Invest"},{"key":"key20240801123844_b93-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N Engl J Med"},{"key":"key20240801123844_b94-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1093\/neuonc\/noac107","article-title":"Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell-mediated toxicity against glioblastoma","volume":"24","author":"Ma","year":"2022","journal-title":"Neuro Oncol"},{"key":"key20240801123844_b95-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"5952","DOI":"10.1158\/1078-0432.CCR-12-3588","article-title":"DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas","volume":"19","author":"Okemoto","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key20240801123844_b96-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/14737140.2021.1882856","article-title":"Pembrolizumab in the adjuvant treatment of melanoma: Efficacy and safety","volume":"21","author":"Nebhan","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20240801123844_b97-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"key":"key20240801123844_b98-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical hodgkin lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20240801123844_b99-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00345-018-2486-1","article-title":"SIU-ICUD recommendations on bladder cancer: Systemic therapy for metastatic bladder cancer","volume":"37","author":"Merseburger","year":"2019","journal-title":"World J Urol"},{"key":"key20240801123844_b100-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.clgc.2021.04.007","article-title":"A phase I\/II study to assess the safety and efficacy of pazopanib and pembrolizumab combination therapy in patients with advanced renal cell carcinoma","volume":"19","author":"Chowdhury","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"key20240801123844_b101-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","article-title":"De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation","volume":"170","author":"Ghoneim","year":"2017","journal-title":"Cell"},{"issue":"e165673","key":"key20240801123844_b102-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.1172\/JCI165673","article-title":"Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models","volume":"133","author":"Li","year":"2023","journal-title":"J Clin Invest"},{"issue":"409","key":"key20240801123844_b103-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20696-x","article-title":"Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"issue":"e004495","key":"key20240801123844_b104-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004495","article-title":"Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors","volume":"10","author":"Papadatos-Pastos","year":"2022","journal-title":"J Immunother Cancer"},{"key":"key20240801123844_b105-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"key20240801123844_b106-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: The CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"key":"key20240801123844_b107-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol"},{"key":"key20240801123844_b108-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol"},{"key":"key20240801123844_b109-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","article-title":"Actively personalized vaccination trial for newly diagnosed glioblastoma","volume":"565","author":"Hilf","year":"2019","journal-title":"Nature"},{"key":"key20240801123844_b110-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"key20240801123844_b111-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"key20240801123844_b112-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol"},{"issue":"283","key":"key20240801123844_b113-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: Mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"key20240801123844_b114-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"key20240801123844_b115-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: A phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol"},{"key":"key20240801123844_b116-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/neuonc\/nov153","article-title":"Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma","volume":"18","author":"Everson","year":"2016","journal-title":"Neuro Oncol"},{"key":"key20240801123844_b117-MCO-21-3-02757","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1093\/neuonc\/now061","article-title":"IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression","volume":"18","author":"Zhang","year":"2016","journal-title":"Neuro Oncol"},{"issue":"E3","key":"key20240801123844_b118-MCO-21-3-02757","doi-asserted-by":"publisher","DOI":"10.3171\/2021.11.FOCUS21489","article-title":"In vivo efficacy of decitabine as a natural killer cell-mediated immunotherapy against isocitrate dehydrogenase mutant gliomas","volume":"52","author":"Zhang","year":"2022","journal-title":"Neurosurg Focus"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T10:32:09Z","timestamp":1722508329000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2024.2757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":118,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,6,28]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2024.2757","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]},"article-number":"59"}}